Free, highly accurate online calculation tool. Process your calculations securely in real time with comprehensive formula transparency, unit flexibility, and instant results.
Model projected weight loss trajectories, weekly titration schedules, and lean mass preservation under GLP-1 receptor agonists (Semaglutide/Wegovy/Ozempic) and dual GIP/GLP-1 agonists (Tirzepatide/Zepbound/Mounjaro).
~15% loss at Week 68; Tirzepatide Benchmark: ~21% loss at Week 72.0.5-1.0% body weight/week; Steady State: 1.0-2.0 lbs/week.Minimum Protein Requirement = 1.2 to 1.6 g/kg (0.6-0.8 g/lb) of total body weight.≥ 3.0 Liters water/day + 500mg sodium/potassium to counter reduced thirst sensation.In benchmark clinical trials (STEP 1 and SURMOUNT-1), Semaglutide 2.4mg achieved an average of ~14.9% total body weight loss at 68 weeks, while Tirzepatide 15mg achieved ~20.9% total body weight loss at 72 weeks.
Gradual monthly dose escalation allows the gastrointestinal tract and central nervous system to adapt to delayed gastric emptying, significantly reducing nausea, vomiting, and reflux.
Without targeted resistance training and high protein intake, 25% to 40% of total weight lost on GLP-1 agonists can come from skeletal muscle mass and lean body tissue.
Clinical extension trials (STEP 1 trial extension) indicate patients regain approximately two-thirds of their lost weight within one year of stopping medication if comprehensive lifestyle changes are not maintained.